PREDICT TB : Prevention of Resistance, Evaluation of Diagnostics and Intensified or Custom-made Treatment of Tuberculosis
(Voorkomen van resistentie, evaluatie van diagnostiek en intensivering van de behandeling van Tuberculose)
View PDF Version
(121116_Steenwinkel, Jurriaan Evert Mathijs de.pdf, 3.4MB)
View PDF Version
(Stellingen behorende bij het proefschrift van JEM de Steenwi.pdf, 1.3MB)
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is still a global health problem of immense proportion. Indeed, TB is considered the second most frequent cause of infectious disease-related death worldwide (after HIV-AIDS). The World Health Organization (WHO) is increasing its efforts to reduce the global threat of TB. Nevertheless, the morbidity and mortality statistics for TB remain shocking. For example, the WHO estimates that the global burden of disease caused by TB in 2010 comprised 8.8 million incident cases, including 1.1 million deaths from TB among HIV-negative individuals, and an additional 0.35 million deaths from HIV-associated TB.1 Additional to these impressive figures is the underlying problem of latent TB infections, with as many as one-third of the world’s population being thought to be latently infected with this bacterium, an immense pool of potential patients around. Further, all current treatment programs tend to be specifically aimed towards the treatment of active TB infection, leaving the huge underlying problem of latent TB infections untouched, essentially meaning that the worldwide elimination of TB is still a distant dream.
The printing of this thesis was financially supported by (in alphabetical order): BD Diagnostic systems, bioMérieux Benelux BV, Eppendorf Nederland BV, Gilead Sciences Netherlands BV, Janssen-Cilag BV, J.E. Jurriaanse Stichting, KN CV Tuberculosis Foundation, Merck Sharp & Dohme BV, Netherlands Society of Medical Microbiology (NVMM) and the Royal Netherlands Society for Microbiology (KN VM), okklo life sciences BV.
- anti-tb drugs
- mtb load